96 related articles for article (PubMed ID: 3390390)
1. Marrow fibroblasts from patients with myeloproliferative disorders show increased sensitivity to human serum mitogens.
Kimura A; Katoh O; Kuramoto A
Br J Haematol; 1988 Jun; 69(2):153-6. PubMed ID: 3390390
[TBL] [Abstract][Full Text] [Related]
2. [Role of PDGF on myeloproliferative disorders].
Kimura A; Katoh O; Kuramoto A
Rinsho Ketsueki; 1988 Jul; 29(7):989-93. PubMed ID: 3184485
[No Abstract] [Full Text] [Related]
3. Platelet derived growth factor messenger RNA is increased in bone marrow megakaryocytes in patients with myeloproliferative disorders.
Katoh O; Kimura A; Itoh T; Kuramoto A
Am J Hematol; 1990 Nov; 35(3):145-50. PubMed ID: 2220756
[TBL] [Abstract][Full Text] [Related]
4. Platelet-derived growth factor is decreased in patients with myeloproliferative disorders.
Katoh O; Kimura A; Kuramoto A
Am J Hematol; 1988 Apr; 27(4):276-80. PubMed ID: 3354562
[TBL] [Abstract][Full Text] [Related]
5. Increased proliferation of bone marrow-derived fibroblasts in primitive hypertrophic osteoarthropathy with severe myelofibrosis.
Fontenay-Roupie M; Dupuy E; Berrou E; Tobelem G; Bryckaert M
Blood; 1995 Jun; 85(11):3229-38. PubMed ID: 7756654
[TBL] [Abstract][Full Text] [Related]
6. Platelet-derived mitogenic activity and bone marrow fibrosis in myeloproliferative disorders.
Romano M; Viero P; Cortellazzo S; Barbui T; Donati MB; Poggi A
Haemostasis; 1990; 20(3):162-8. PubMed ID: 2143744
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast colony-forming cells with high sensitivity to serum mitogen(s) exist in bone marrow of patients with chronic myelocytic leukemia.
Kimura A; Katoh O; Hyodo H; Kusumi S; Kuramoto A
Eur J Haematol; 1990 May; 44(5):291-5. PubMed ID: 2369940
[TBL] [Abstract][Full Text] [Related]
8. Properties of myelofibrosis-derived fibroblasts.
Castro-Malaspina H; Jhanwar SC
Prog Clin Biol Res; 1984; 154():307-22. PubMed ID: 6382300
[TBL] [Abstract][Full Text] [Related]
9. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation.
Dalley A; Smith JM; Reilly JT; Neil SM
Br J Haematol; 1996 Jun; 93(4):856-62. PubMed ID: 8703817
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of bone marrow fibroblast colony-forming cells (CFU-F) and their progeny in patients with myeloproliferative disorders.
Castro-Malaspina H; Gay RE; Jhanwar SC; Hamilton JA; Chiarieri DR; Meyers PA; Gay S; Moore MA
Blood; 1982 May; 59(5):1046-54. PubMed ID: 7042002
[TBL] [Abstract][Full Text] [Related]
11. Increased growth and collagen synthesis of bone marrow fibroblasts from patients with chronic myelocytic leukaemia.
Yonekura S; Nagao T; Arimori S
Br J Haematol; 1985 Sep; 61(1):93-9. PubMed ID: 3863668
[TBL] [Abstract][Full Text] [Related]
12. Histologic criteria for classification and differential diagnosis of chronic myeloproliferative disorders.
Frisch B; Bartl R; Burkhardt R; Jäger K
Haematologia (Budap); 1984; 17(2):209-26. PubMed ID: 6534829
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta regulates growth as well as collagen and fibronectin synthesis of human marrow fibroblasts.
Kimura A; Katoh O; Hyodo H; Kuramoto A
Br J Haematol; 1989 Aug; 72(4):486-91. PubMed ID: 2789074
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow lymphoid nodules in myeloproliferative disorders: association with the nonmyelosclerotic phases of idiopathic myelofibrosis and immunological significance.
Cervantes F; Pereira A; Marti JM; Feliu E; Rozman C
Br J Haematol; 1988 Nov; 70(3):279-82. PubMed ID: 3207625
[TBL] [Abstract][Full Text] [Related]
15. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
16. Increased fibroblast colony stimulating activity (F-CSA) in serum of myeloproliferative disorders.
Han ZC; Briere J; Parent D; Abgrall JF; Sensebe L
J Biol Regul Homeost Agents; 1988; 2(3):119-24. PubMed ID: 3267102
[TBL] [Abstract][Full Text] [Related]
17. Changes in the mitogenic activity of platelet-derived growth factor(s) in patients with myeloproliferative disease.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Masiero M; Sgarabotto D; Girolami A
Acta Haematol; 1989; 81(3):131-5. PubMed ID: 2496560
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD).
Wróbel T; Mazur G; Surowiak P; Wolowiec D; Jelen M; Kuliczkowsky K
Pathol Oncol Res; 2003; 9(3):170-3. PubMed ID: 14530810
[TBL] [Abstract][Full Text] [Related]
19. A reversible defect of platelet PDGF content in myeloproliferative disorders.
Baglin TP; Price SM; Boughton BJ
Br J Haematol; 1988 Aug; 69(4):483-6. PubMed ID: 3408684
[TBL] [Abstract][Full Text] [Related]
20. Increased circulating CSF-1 (M-CSF) in myeloproliferative disease: association with myeloid metaplasia and peripheral bone marrow extension.
Gilbert HS; Praloran V; Stanley ER
Blood; 1989 Sep; 74(4):1231-4. PubMed ID: 2669997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
